



## Reverse Vaccinology and Genomics

Guest Editor:

**Dr. Daniel Dory**

ANSES - French Agency for Food,  
Environmental and Occupational  
Health & Safety, Ploufragan-  
Plouzane-Niort Laboratory, Viral  
Genetics and Biosafety Unit,  
22440 Ploufragan, France

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

Novel strategies based on the analysis of the pathogens' genome developed over the last years enable to identify efficient vaccine antigens. These strategies are known under the name of reverse vaccinology. At the beginning, it consisted in manual screening of hundreds of potential proteins of the pathogen. Thereafter in silico analyses, using specific software and databases, helped to identify Open Reading Frames (ORFs) encoding potential vaccine antigens. Thus, only a low number of vaccine candidates has to be evaluated in vivo for their protective potentials. Such studies were first performed to develop new human vaccines. There is a need to develop specific reverse vaccinology tools for veterinary purposes. The aim of this specific issue will be to publish papers describing the development or optimization of human or veterinary vaccines identified through reverse vaccinology strategies. Another part of this issue will be the description of novel reverse vaccinology tools, including those specifically dedicated to veterinary species. A special interest will be on the development of tools potentially detecting T-cell antigens.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)